Journal article
Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma
WW Busse, P Paggiaro, X Muñoz, TB Casale, M Castro, GW Canonica, JA Douglass, Y Tohda, N Daizadeh, B Ortiz, N Pandit-Abid
European Respiratory Journal | EUROPEAN RESPIRATORY SOC JOURNALS LTD | Published : 2021
Open access
Abstract
Dupilumab treatment versus placebo improved exacerbation rate and lung function outcomes in patients with uncontrolled moderate-to-severe asthma and high type 2 biomarkers at baseline, regardless of baseline characteristics in the phase 3 QUEST study https://bit.ly/3yR7MlD
Grants
Funding Acknowledgements
Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. Funding information for this article has been deposited with the Crossref Funder Registry.